335 related articles for article (PubMed ID: 22819198)
1. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
[TBL] [Abstract][Full Text] [Related]
2. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
[TBL] [Abstract][Full Text] [Related]
3. Janus kinases to jakinibs: from basic insights to clinical practice.
Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of Janus kinases.
Pesu M; Laurence A; Kishore N; Zwillich SH; Chan G; O'Shea JJ
Immunol Rev; 2008 Jun; 223():132-42. PubMed ID: 18613833
[TBL] [Abstract][Full Text] [Related]
5. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
6. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitors: Ten years after.
Spinelli FR; Meylan F; O'Shea JJ; Gadina M
Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
10. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
Xu P; Shen P; Yu B; Xu X; Ge R; Cheng X; Chen Q; Bian J; Li Z; Wang J
Eur J Med Chem; 2020 Apr; 192():112155. PubMed ID: 32120325
[TBL] [Abstract][Full Text] [Related]
11. Janus kinases: an ideal target for the treatment of autoimmune diseases.
Gadina M
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S70-2. PubMed ID: 24326567
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
Cornez I; Yajnanarayana SP; Wolf AM; Wolf D
Mol Cell Endocrinol; 2017 Aug; 451():88-96. PubMed ID: 28131742
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
14. Advances in the discovery of selective JAK inhibitors.
Menet CJ; Rompaey LV; Geney R
Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors in autoimmune diseases.
O'Shea JJ; Kontzias A; Yamaoka K; Tanaka Y; Laurence A
Ann Rheum Dis; 2013 Apr; 72 Suppl 2(0 2):ii111-5. PubMed ID: 23532440
[TBL] [Abstract][Full Text] [Related]
16. Translating JAKs to Jakinibs.
Gadina M; Chisolm DA; Philips RL; McInness IB; Changelian PS; O'Shea JJ
J Immunol; 2020 Apr; 204(8):2011-2020. PubMed ID: 32253269
[TBL] [Abstract][Full Text] [Related]
17. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Quintás-Cardama A; Kantarjian H; Cortes J; Verstovsek S
Nat Rev Drug Discov; 2011 Feb; 10(2):127-40. PubMed ID: 21283107
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
20. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
